Free Trial

ADC Therapeutics (ADCT) Competitors

ADC Therapeutics logo
$4.16 -0.10 (-2.35%)
Closing price 10/16/2025 03:59 PM Eastern
Extended Trading
$4.12 -0.04 (-0.84%)
As of 10/16/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADCT vs. COGT, TLRY, ABCL, IMCR, HROW, BHVN, EWTX, VCEL, GPCR, and HRMY

Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Cogent Biosciences (COGT), Tilray Brands (TLRY), AbCellera Biologics (ABCL), Immunocore (IMCR), Harrow (HROW), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Vericel (VCEL), Structure Therapeutics (GPCR), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.

ADC Therapeutics vs. Its Competitors

Cogent Biosciences (NASDAQ:COGT) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

In the previous week, ADC Therapeutics had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 9 mentions for ADC Therapeutics and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.63 beat ADC Therapeutics' score of -0.10 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cogent Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ADC Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

41.1% of ADC Therapeutics shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cogent Biosciences presently has a consensus target price of $19.67, indicating a potential upside of 20.21%. ADC Therapeutics has a consensus target price of $7.50, indicating a potential upside of 80.29%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Cogent Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cogent Biosciences
1 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.71
ADC Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Cogent Biosciences has a net margin of 0.00% compared to ADC Therapeutics' net margin of -220.00%. ADC Therapeutics' return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cogent BiosciencesN/A -223.82% -89.44%
ADC Therapeutics -220.00%N/A -53.73%

Cogent Biosciences has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.

ADC Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cogent BiosciencesN/AN/A-$255.86M-$1.78-9.19
ADC Therapeutics$70.84M6.61-$157.85M-$1.57-2.65

Summary

ADC Therapeutics beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks.

Get ADC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADCT vs. The Competition

MetricADC TherapeuticsMED IndustryMedical SectorNYSE Exchange
Market Cap$479.25M$3.41B$6.09B$21.97B
Dividend YieldN/A2.29%5.73%3.59%
P/E Ratio-2.6522.9385.0732.64
Price / Sales6.61486.15604.9982.90
Price / CashN/A46.9737.8624.53
Price / Book-1.9810.5012.394.62
Net Income-$157.85M-$52.47M$3.32B$1.01B
7 Day Performance-9.37%-1.00%-0.24%-0.79%
1 Month Performance25.68%14.49%9.56%0.25%
1 Year Performance29.19%13.92%71.67%11.51%

ADC Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADCT
ADC Therapeutics
2.256 of 5 stars
$4.16
-2.3%
$7.50
+80.3%
+29.2%$479.25M$70.84M-2.65310News Coverage
Analyst Forecast
COGT
Cogent Biosciences
1.8218 of 5 stars
$15.90
+0.9%
$20.00
+25.8%
+44.1%$1.79BN/A-8.9380News Coverage
Analyst Forecast
High Trading Volume
TLRY
Tilray Brands
3.1996 of 5 stars
$1.58
-2.5%
$1.94
+22.6%
-2.5%$1.78B$821.31M-0.682,842Trending News
Earnings Report
Options Volume
ABCL
AbCellera Biologics
2.3363 of 5 stars
$5.87
-0.5%
$8.00
+36.3%
+122.9%$1.76B$28.83M-10.67500
IMCR
Immunocore
2.3337 of 5 stars
$34.01
-0.6%
$56.89
+67.3%
+0.8%$1.72B$310.20M-85.03320
HROW
Harrow
2.9582 of 5 stars
$42.16
-7.2%
$68.50
+62.5%
-30.8%$1.68B$199.61M-168.64180High Trading Volume
BHVN
Biohaven
3.4178 of 5 stars
$15.93
+0.8%
$48.85
+206.6%
-68.1%$1.67BN/A-2.08239
EWTX
Edgewise Therapeutics
2.9432 of 5 stars
$15.35
-1.9%
$38.83
+153.0%
-56.3%$1.65BN/A-9.9060
VCEL
Vericel
3.3507 of 5 stars
$33.74
+4.0%
$60.40
+79.0%
-15.8%$1.64B$237.22M281.19300Trending News
Analyst Upgrade
Analyst Revision
GPCR
Structure Therapeutics
3.4123 of 5 stars
$28.68
+5.1%
$68.67
+139.4%
-29.3%$1.57BN/A-27.31136
HRMY
Harmony Biosciences
4.7734 of 5 stars
$26.59
-2.5%
$45.50
+71.1%
-25.5%$1.57B$714.73M8.58200Positive News
Analyst Forecast

Related Companies and Tools


This page (NYSE:ADCT) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners